What does this article add?
CYC is a better option for the first line treatment of ILD in systemic
sclerosis , rheumatoid arthritis and primary sjögren syndrome patients
compared to AZA treatment. AZA could be an alternative option in
inflammatory myositits associated ILD and interstitial pneumonia with
autoimmune features with limited disease extent .